NCT04360434View on ClinicalTrials.gov

First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Amyloid Transthyretin Cardiomyopathy
Interventions
DRUG

NI006

NI006 will be administered intravenously

DRUG

Placebo

Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously

Trial Locations (6)

9713

University Medical Center Groningen, Groningen

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

31059

CHU Toulouse - Hôpital Rangueil, Toulouse

35033

CHU de Rennes - Hôpital Pontchaillou, Rennes

69120

Universitätsklinikum Heidelberg, Heidelberg

94000

Hôpital Henri Mondor, Créteil

Sponsors

Lead Sponsor

Neurimmune AG
All Listed Sponsors
lead

Neurimmune AG

INDUSTRY

NCT04360434 - First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy | Biotech Hunter | Biotech Hunter